Clinical Trials Logo

Clinical Trial Summary

Refractive outcome after cataract surgery mainly depends on the prediction of the intraocular lens that is implanted in the eye during surgery.

Aim of this study is to measure the position of the lens capsule during surgery and to use this measurements to improve post-operative refractive outcomes.


Clinical Trial Description

During the last decades the refractive outcome after cataract surgery improved significantly.

The total prediction error in IOL power calculation (and therefore in the refractive outcome) can be divided into 3 main parameters:

- Axial eye length (in mm)

- Corneal power (in dioptres)

- Estimation of post-operative anterior chamber depth (ACD) (in mm)

Since the introduction of optical biometry (IOLMaster, Carl Zeiss Meditec AG, Jena, Germany), as a reliable non-contact measurement of the axial eye length the influence of the error of axial length measurement on the refractive error decreased from over 50% (when measured with applanation ultrasound) to 36%. The mean error of corneal power measurement is approximately 22%.

These results show that the estimation of the post-operative intra-ocular lens (IOL) position and therefore the estimated anterior chamber depth (ACD) is nowadays the main source of error (35%to 42%) in IOL power calculation and therefore for the refractive outcome of the patients after cataract surgery.

Early IOL power calculation formulas, such as the Binkhorst I formula, used a fixed ACD value to predict the position of the IOL, but the refractive results were not appropriate, because the post-operative position of the IOL varied significantly between patients. Later observations showed a correlation between the axial eye length and the post-operative ACD (longer=more myopic eyes showed a larger ACD post-operatively). These correlations were taken into account in later developed formulas (such as the Binkhorst II formula).

Olsen et al. measured the post-operative ACD and substituted the predicted post-operative ACD with the true, post-operative ACD in each case. The result after correcting the IOL position was a highly accurate IOL power calculation, where no fudge factors were needed.

Nowadays the pre-operatively measured ACD is taken into account for several IOL power calculation formulas, such as the Haigis formula, the Holladay II formula and the Olsen formula.

However, this new generation of formulas uses the pre-operative ACD, without considering the thickness of the crystalline lens. The ACD is measured as the distance between the anterior surface of the cornea (anatomically correct would be the posterior surface of the cornea, but in an optical context, as in IOL power calculations, the anterior surface is used) and the anterior surface of the crystalline lens . Therefore the thickness of the crystalline lens has a significant impact on the predicted post-operative position of the IOL. This parameter was first taken into account by Olsen and later modified by Norrby.

It should be mentioned that IOL power calculations developed from theoretical calculations based on Gaussian optics to regression formulas, such as the SRK formula 11 that uses retrospective data of a large number of patients. Nowadays ray tracing is available that uses a numerical solution to calculate the IOL power.

All these findings suggest that a proper measurement of the position and the size of the crystalline lens as well as of the lens capsule after removing the crystalline lens is necessary to improve IOL power calculation.

Recently a device was introduced that allows measurements of the crystalline lens as well as the lens capsule itself after removing the crystalline lens of cataract patients intra-operatively. This device uses optical coherence tomography (OCT) technology to create high resolution B-scans (=images) of the anterior segment of the eye. The OCT was shown to be highly reproducible for ACD measurements pre-operatively and small changes of the IOL/crystalline lens can be detected.

The intra-operative OCT may allow measurements of the crystalline lens, of the lens capsule and furthermore of the position of the IOL intra-operatively. Therefore it may be possible for the first time, to directly observe the correlation of the position and size of the crystalline lens to the IOL position intra-operatively.

Number of subjects In total, 50 eyes of 50 subjects will be included.

- Standard eyes (IOL power 18 - 23 D): 30 eyes

- Long (myopic) eyes (IOL power < 18 D) - 10 eyes

- Short (hyperopic) eyes (IOL power > 23 D) - 10 eyes

Study Visits On the day of pre-operative examination, the patient will undergo a full ophthalmic assessment and routine biometry will be performed for axial length measurement and Keratometry (IOLMaster, Carl Zeiss Meditec AG, Jena, Germany). Furthermore pre-operatively the ACD and lens thickness (LT) will be measured (ACMaster, Carl Zeiss Meditec AG, Jena, Germany).

Surgery is performed in topical anaesthesia. The standard preoperative therapy is tropicamide 1% gtt, phenylephrine 2.5% gtt, cyclopentolate 1% gtt. An on-axis self-sealing incision, injection of viscoelastic substance, capsulorhexis, phacoemulsification, irrigation/aspiration of cortical material are performed as standard procedure. After measurement, the IOL will be implanted using the dedicated injector system.

Intra-operative study-related measurements:

OCT scans will be performed at 4 different stages intra-operatively:

1. At the beginning of the surgery

2. After removing the natural crystalline lens with phakoemulsification and irrigation/aspiration (I/A). The infusion handpiece of the I/A set (that is used routinely) will be placed into the paracentesis and the bottle height will be adjusted to control the pressure in the anterior chamber. It will be set to result in an estimated pressure of approximately 20mmHg. Therefore a hydraulic table with memory function will be used that can be set at exactly the same height for each patient and the infusion bottle will be placed at a height of 27cm above the eye (27.2cmH2O = 20mmHg). Then an OCT scan will be performed.

3. Then ophthalmic viscosurgical device (OVD) is inserted and a capsular tension ring (CTR) will be implanted. Therefore the OVD is irrigated and aspirated and the measurement repeated.

4. Afterwards the IOL is implanted and the viscoelastic is removed.

Outcome variables

Main outcome variable:

- Intra-operative posterior capsule position with CTR in place Additional outcome variable

- Posterior capsule position in phakic eyes

- Posterior capsule position intra-operatively without CTR

- Comparison of posterior capsule position of eyes with different axial eye length ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01867541
Study type Observational
Source Vienna Institute for Research in Ocular Surgery
Contact
Status Completed
Phase N/A
Start date December 2010
Completion date March 2013

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06005675 - User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
Active, not recruiting NCT01382641 - Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Phase 4
Completed NCT01382823 - Laser Cataract Surgery With the Femtosecond Laser Technology Phase 4
Completed NCT05991960 - Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
Active, not recruiting NCT05574959 - Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V N/A
Completed NCT02492659 - Clinical Research of Femtosecond Laser-Assisted Cataract Surgery N/A
Completed NCT01279031 - Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial Phase 4
Completed NCT01061463 - Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study N/A
Completed NCT01021761 - A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Phase 4
Completed NCT00999492 - Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront Phase 4
Completed NCT01001806 - A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Phase 4
Completed NCT00542581 - Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D. N/A
Completed NCT03708367 - A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice N/A
Completed NCT05575063 - Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD) N/A
Recruiting NCT05531292 - PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002 N/A
Completed NCT05058274 - Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
Completed NCT05053399 - Evaluation of the TECNIS Symfony® Toric Intraocular Lens N/A
Recruiting NCT02639845 - Eye Drop Application Monitor, Pilot Study N/A
Completed NCT01684007 - A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients N/A
Completed NCT00827073 - Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery N/A